Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment

被引:11
作者
Pozdnyakova, Olga [1 ]
Crowley-Larsen, Patricia [2 ]
Zota, Victor [1 ]
Wang, Sa A. [3 ]
Miron, Patricia A. [1 ,2 ]
机构
[1] UMass Mem Med Ctr, Dept Pathol, Worcester, MA 01605 USA
[2] UMass Mem Med Ctr, Dept Hosp Labs, Worcester, MA 01605 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
IN-SITU HYBRIDIZATION; MULTIPLE-MYELOMA; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; CYTOGENETICS; INSIGHTS;
D O I
10.1016/j.cancergencyto.2008.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Historically, cytogenetic studies of plasma cell neoplasms have been hampered by the fact that terminally differentiated plasma cells do not proliferate well in vitro. Although the use of interphase FISH (iFISH) has greatly improved the ability to detect cytogenetic abnormalities, cases with low numbers of neoplastic cells often do not demonstrate abnormalities. Using a four-assay, nine-probe iFISH panel, we compared the abnormality detection rate for overnight unstimulated bone marrow cultures (ONC) to that for plasma-cell enriched fractions obtained with use of CD138-coated immunomagnetic beads (PCE). In the ONC, an abnormality was detected in I I of 29 cases (38%); in the PCE, an abnormality was detected in 30 of 33 cases (91%). For 28 cases in which iFISH results from ONC were compared directly with PCE samples, the overall abnormality rate was 36% for ONC and 89% for PCE (P < 0.01). The conventional GTG-banded chromosome analysis revealed only 2 of 34 cases with an abnormal karyotype (6%); both cases were hyperdiploid. We conclude that the plasma cell enrichment step for iFISH should be incorporated into the routine cytogenetic work-up for all patients with plasma cell neoplasms. (C) 2009 Elsevier Inc. All fights reserved.
引用
收藏
页码:112 / 117
页数:6
相关论文
共 22 条
[1]  
Barch M., 1997, AGT CYTOGENETICS LAB
[2]   Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma [J].
Chiecchio, L. ;
Protheroe, R. K. M. ;
Ibrahim, A. H. ;
Cheung, K. L. ;
Rudduck, C. ;
Dagrada, G. P. ;
Cabanas, E. D. ;
Parker, T. ;
Nightingale, M. ;
Wechalekar, A. ;
Orchard, K. H. ;
Harrison, C. J. ;
Cross, N. C. P. ;
Morgan, G. J. ;
Ross, F. M. .
LEUKEMIA, 2006, 20 (09) :1610-1617
[3]   Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark [J].
Christensen, Jacob H. ;
Abildgaard, Niels ;
Plesner, Torben ;
Nibe, Anne ;
Nielsen, Ole ;
Sorensen, Anne G. ;
Kerndrup, Gitte B. .
CANCER GENETICS AND CYTOGENETICS, 2007, 174 (02) :89-99
[4]  
DEWALD GW, 1985, BLOOD, V66, P380
[5]   Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement [J].
Draube, A ;
Pfister, R ;
Vocherodt, M ;
Schuster, S ;
Kube, D ;
Diehl, V ;
Tesch, H .
ANNALS OF HEMATOLOGY, 2001, 80 (02) :83-89
[6]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575
[7]   Genomic abnormalities in monoclonal gammopathy of undetermined significance [J].
Fonseca, R ;
Bailey, RJ ;
Ahmann, GJ ;
Rajkumar, SV ;
Hoyer, JD ;
Lust, JA ;
Kyle, RA ;
Gertz, MA ;
Greipp, PR ;
Dewald, GW .
BLOOD, 2002, 100 (04) :1417-1424
[8]  
Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876
[9]  
GOULD J, 1988, BLOOD, V71, P453
[10]   Cytogenetics of multiple myeloma:: interpretation of fluorescence in situ hybridization results [J].
Harrison, CJ ;
Mazzullo, H ;
Cheung, KL ;
Gerrard, G ;
Jalali, GR ;
Mehta, A ;
Osier, DG ;
Orchard, KH .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :944-952